source
- Pfizer halts phase 2 trial of CXCR5 antibody for immune thrombocytopeniaPfizer announced it is ending a phase 2 study of its CXCR5-targeting antibody PF-06835375 in patients with primary immune thrombocytopenia (ITP). The decision was described as a business decision a…
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…